The call ran from 10:58 AM to 11:45 AM IST (47 min).
Key takeaways
Q2 revenue ₹23.29 Cr, up 62% QoQ but down 23% YoY; EBITDA margin fell to 17% from 32%. Management's 'stronger performance ahead' has no numbers, and it admits the recovery is incomplete.
| Revenue growth | Revenue ₹23.29 Cr: +62% QoQ, -23% YoY; recovering from weak Q1. |
|---|---|
| Margins | EBITDA margin 17% vs 23% Q1 and 32% Q2 FY26; contracting. |
| Demand visibility | European demand subdued; domestic pivot; RFQs rising; no volume outlook. |
| Management confidence | Balanced; admits recovery incomplete; optimism largely qualitative. |
Growth
Revenue +62% QoQ off weak Q1, but -23% YoY. EBITDA -59% YoY; PAT -67% YoY.
Outlook
No revenue or margin guidance given. Commercial supply from Q1 FY28; ~80% plant utilisation at peak, in three years.
Risks
Opex +76% vs revenue +62%; European order deferrals; inventory build-up; no firm commercial supply date beyond Q1 FY28.
Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›
The results behind this call
Shree Ganesh Remedies Q2 FY27 Results: Net Profit ₹1.6 Cr, Down 68.0% YoY
Shree Ganesh Remedies' board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Revenue from operations for the half year was Rs 3,765.47 lakhs, down from Rs 5,498.29 lakhs a year earlier.
- Key figure
- Net profit ₹1.6 Cr · -68.0% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Block-7 commercial production starts Q2 FY27; CRAMS projects transitioning to commercial trials; sustainable EBITDA margins targeted at 26-28%.
Growth they described
Q4 FY26 revenue grew 36% YoY and 57% QoQ; EBITDA grew 15% YoY; PAT declined 5% YoY to INR 6.27 cr.
Call details
| Company | Shree Ganesh Remedies Ltd |
|---|---|
| NSE symbol | SGRL |
| ISIN | INE414Y01015 |
| Call | Q2 FY27 earnings call |
| Date | Saturday, 14 November 2026 |
| Time | 11:00 AM IST |
| Length | 47 min |
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹605.80
- Market cap
- ₹777.7 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 64.2×Sector 49.0×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.